Wegovy
The latest news about Wegovy: headlines, AI summaries and the full story from every source.
- GLP-1 Drugs Are Changing Eating Habits and Impacting Food Industry Revenue
- Patients Switching to Oral Wegovy Continue Weight Loss in Real-World Study
- Viatris Sues Novo Nordisk Over Generic Version of Wegovy
- Novo Nordisk outlines growth strategy amid Eli Lilly's expanding GLP-1 lead
- Eli Lilly and Novo Nordisk Compete Over Next-Phase Obesity Drug Innovations
- Novo Nordisk's Investor Day Fails to Excite Market
- Novo Nordisk Announces New Drug Pipeline Amid Investor Skepticism
- Novo Nordisk Stock Falls Amid Pipeline Concerns
- Novo Nordisk Expands Obesity Drug to Children Amid Market Hesitation
- Eli Lilly's Foundayo Gains Rapid Market Share in Oral Weight-Loss Segment
- Novo Nordisk's Pediatric Obesity Drug Trial Shows Promise, But Commercial Success Uncertain
- Oral Wegovy Surpasses Eli Lilly's Zepbound as Top-Selling Weight-Loss Drug
- Oral Wegovy Captures One-Third of Prescriptions as Adoption Accelerates
- Eli Lilly Aims to Leverage GLP-1 Success for Future Acquisitions
- Novo Nordisk Stock Faces Challenges Amid Competition and Clinical Setbacks
- Novo Nordisk Launches Wegovy Weight Loss Pill in UAE, Expanding Beyond US Market
- CVS Health Restores Coverage for Eli Lilly’s Zepbound and Adds Obesity Pill
- Novo Nordisk Receives EU Approval for Higher-Dose Wegovy in Single-Dose Pen
- Novo Nordisk Expands Wegovy's Global Reach Beyond U.S. Market
- Novo Nordisk Reports High-Dose Wegovy Achieves Nearly 28% Weight Loss in Some Patients
- Novo Nordisk Faces Pricing Pressure Amid Strong Demand and Competition from Eli Lilly
- Novo Nordisk Reports Strong Q1 Results Driven by Wegovy Weight-Loss Pill
- Novo Nordisk Q1 Earnings Beat Expectations Due to Strong Wegovy Demand
- Novo Nordisk Raises 2026 Outlook Amid Strong Demand for Obesity Drugs
- Novo Nordisk Raises Guidance as Wegovy Sales Exceed Expectations
- Novo Nordisk Raises Outlook Slightly as Q1 Profit Exceeds Forecast
- Novo Nordisk's Wegovy Pill Boosts GLP-1 Market, Challenges Eli Lilly's Position